Yesterday, small cap dental stock BIOLASE Inc (NASDAQ: BIOL) surged 17.69% after announcing it had received a license from the Health Canada-Medical Device Bureau to sell its EPIC dental soft-tissue diode laser systems throughout Canada, meaning its worth taking a closer look at the stock along with the performance of mid cap dental stocks like Sirona Dental Systems, Inc (NASDAQ: SIRO), DENTSPLY International Inc (NASDAQ: XRAY) and Align Technology, Inc (NASDAQ: ALGN).
What is BIOLASE Inc?Small cap BIOLASE Inc specializes in the development, manufacturing and marketing of lasers and related products to provide biological treatments that eliminate pain and are safer for patients. More specifically,�BIOLASE Inc offers flagship and best-selling laser systems such as the WaterLase iPlus��and WaterLase MDX�⒙�hile the latest addition to its�product lineup is the EPIC��Total Diode Solution�- a soft tissue laser. Today, the company is #1 in dental lasers with more than 23,000 dental lasers installed worldwide since 1998, including over 9,800 WaterLase systems in over 70 countries, plus it�� the #1 manufacturer of lasers in the USA.
Top 5 High Dividend Companies To Watch For 2015: Veeco Instruments Inc.(VECO)
Veeco Instruments Inc., together with its subsidiaries, designs, manufactures, and markets various equipments to make light emitting diodes (LEDs) and hard-disk drives worldwide. The company?s LED and Solar segment designs and manufactures metal organic chemical vapor deposition and molecular beam epitaxy systems and components for the manufacturers of LEDs, wireless devices, power semiconductors, and concentrator photovoltaics, as well as to research and development applications. Its Data Storage segment designs and manufactures various technologies, including ion beam etch, ion beam deposition, diamond-like carbon, physical vapor deposition, chemical vapor deposition, and slicing, dicing, and lapping systems to create thin film magnetic heads that read and write data on hard disk drives. The company was founded in 1945 and is headquartered in Plainview, New York.
Advisors' Opinion:- [By Vera Yuan]
Among a few stocks that had negative returns in the quarter, Veeco Instruments (VECO) and Titan International (TWI) are also among the smaller positions in the portfolio. Titan, which declined 11.4% in the quarter and will be discussed later in this letter, is a relatively new stock in the portfolio and one that we added to as the share price declined.Among the stocks that we added to in the quarter were Atwood Oceanics (ATW) and Titan International (TWI).As mentioned above, Titan declined nearly 12% in the quarter and we added to the position as the stock weakened. As you may recall, we initiated the position in TWI in the fourth quarter of 2013 in the mid- teens. Despite our additional TWI purchases, we do not yet own a full position in the stock. However, we have plenty of capacity to take the stock to a normal full position, which is 3%, but this assumes the company earns the right to have more of your capital allocated to the position.The primary reason why TWI shares sold off recently is that the wheel and tire markets for large construction and mining equipment remain depressed. Investors had hoped that the off-road, large construction equipment and mining business would see some acceleration after the very cold winter season, but that does not appear to be the case. Tire inventory levels for large, off-road equipment were too high for dealers to be aggressive and purchase tires en masse earlier this year. However, there is some recent evidence that much of the excess tire inventory has been reduced to levels that now support some restocking.Our investment thesis for TWI is not predicated on the wheel and tire market for large, off-road equipment to come roaring back to levels experienced before the financial crisis. Rather we believe the assets TWI has accumulated over the past decade can be managed more efficiently and, therefore, profit margins can improve without a huge increase in revenues. We recently visited one of TWI�� Midwest tire facilities a
- [By Victor Selva]
On Nov. 21, Robert Karr bought Veeco Instruments Inc. (VECO), a company that designs, manufactures and markets equipment to make light emitting diodes (LEDs), solar panels, hard-disk drives and other devices.
- [By Rick Munarriz]
1. Veeco Industries will post a larger loss than analysts are expecting
Veeco Industries (NASDAQ: VECO ) is a provider of process equipment solutions that assist the making of LEDs, flexible OLEDs, power electronics, hard drives, MEMS, and wireless chips. Unfortunately for investors it also has been posting a lot of red ink lately. - [By Brian Pacampara]
What: Shares of LED equipment maker Veeco Instruments (NASDAQ: VECO ) soared 17% today after its first-quarter bookings and business update impressed�Wall Street. �
Top 5 Tech Stocks To Own For 2014: ImmunoCellular Therapeutics Ltd (IMUC)
ImmunoCellular Therapeutics, Ltd., incorporated on March 20, 1987, is a clinical-stage biotechnology company. The Company is engaged in developing immune-based therapies for the treatment of cancers, such as brain, ovarian and other solid tumors. Immunotherapy is an approach to treat cancer in which a patient�� own immune system is stimulated to target tumor antigens, which are molecular signals that the immune system uses to identify foreign bodies. The Company�� products include ICT-107, ICT-140, ICT-120, ICT-109 and DIAAD. ICT-107, the pipeline product, is a Phase II therapeutic dendritic cell (DC) vaccine for the treatment of glioblastoma multiforme (GBM), the common and lethal type of brain cancer. ICT-107 is designed to activate a patient�� immune system to target six different tumor-associated antigens. In February 2012, it acquired a world-wide license from the University of Pennsylvania and The John Hopkins University (JHU).
The Company in addition to ICT-107, is also developing other therapeutic DC vaccines: ICT-140 for ovarian cancer and ICT-121 for recurrent GBM. ICT-140 targets seven tumor-associated antigens expressed on ovarian cancer cells. ICT-107 is a DC vaccine that targets six different tumor-associated antigens that are found on patients��tumor cells; four of the six antigens are expressed on CSCs. The therapeutic vaccine is used subsequent to conventional therapy or concomitantly with chemotherapy in patients with newly diagnosed GBM. ICT-140 is a DC vaccine that targets seven different ovarian cancer antigens. ICT-121 is a DC vaccine that targets CD133 antigens; it has the potential to be a universal cancer vaccine because CD133 is widely expressed on CSCs from a majority of cancers. Data from this small study demonstrated that ICT-109 had a statistically ability to discriminate between cancerous and non-cancerous samples, suggesting the potential to detect pancreatic and lung cancer in plasma and serum study sets. The DIAAD (differential immunization for an! tigen and antibody discovery) platform it acquired from Molecular Discoveries utilizes immunological tolerization to accelerate the discovery of the molecular differences between diseased cells and their normal counterparts. The monoclonal antibodies produced by DIAAD provide the basis for the discovery and development of its potential diagnostic and therapeutic products.
The Company competes with Dendreon, Oncothyreon, Galena, Bavarian Nordic and Immunovaccine, Northwest Biotherapeutics, Prima Biomed, DCPrime, Roche/Genentech, Seattle Genetics, Bristol-Myers Squibb and Immunogen.
Advisors' Opinion:- [By Monica Gerson]
ImmunoCellular Therapeutics (NYSE: IMUC) dropped 11.05% to $1.3699. ImmunoCellular's trailing-twelve-month ROE is -59.80%.
Posted-In: market losersNews Movers & Shakers Intraday Update Markets
- [By Smith On Stocks]
Using my assumptions, the common of Agenus might be worth about $7.00 per share in early 2014 based on the royalties from the Glaxo vaccines and the net operating loss carry forward even if every other asset in the company were valued at zero. However, there may be substantial value in Agenus' internal vaccine programs in recurrent and newly diagnosed glioblastoma and the genital herpes vaccine. Based on a comparison to peer companies like Northwest Biotherapeutics (NWBO) and ImmunoCellular Therapeutics (IMUC), I believe that the internal programs at Agenus currently may be worth $150 million or $4.45 per share. Adding this to the value of the MAGE A-3 vaccine could produce a stock price of $11.00 in early 2014.
- [By Lauren Pollock]
ImmunoCellular Therapeutics Ltd.(IMUC) said its leading product candidate, a dendritic cell-based vaccine for brain cancer, didn’t show a statistically significant advantage in overall survival in a Phase II study. In a research note, Maxim Group said it is pushing its EU approval date target to 2019 and lowered its estimate on the stock to $12 a share from $18 a share. The stock plunged 62% to $1.04 premarket.
- [By Wallace Witkowski]
Shares of ImmunoCellular (IMUC) �jumped after the drug developer said data on a mid-stage brain cancer drug study were looking encouraging.
Top 5 Tech Stocks To Own For 2014: GTT Communications Inc (GTT)
GTT Communications, Inc., formerly Global Telecom & Technology, Inc., incorporated on January 3, 2005, is a global network integrator providing a portfolio of Wide-Area Network (WAN), dedicated Internet access and managed data services. The Company combines multiple networks and technologies, such as traditional OC-x, MPLS and Ethernet, to deliver solutions designed for each client�� requirements. The Company improves its client performance through its Client Management Database (CMD), providing customers with an integrated support system for all of their services. It is provides solutions, project management and 24x7 global operations support. In May 2012, the Company acquired nLayer Communications Inc. In April 2013, Neutral Tandem Inc acquired the global data services business of Global Telecom & Technology Inc.
The Company�� global operations consist of two parts: global customer operations, and global network operations and engineering. Customer operations include project management and development of its CMD system. Global project management assures the implementation of a customer services after the sale. Network operations and engineering consists of global Network Operations Center (NOC) and Engineering and Information and Communications Technology (ICT). The NOC receives, prioritizes, tracks and resolves network outages or other customer needs, along with provisioning and testing of services. Engineering provides support for the NOC and the sales team, as well as carrying out all provisioning for GTT Network Services. ICT manages all internal desktop, and network and server infrastructure.
The Company competes with Level 3, Qwest, KPN, XO Communications, COLT, Verizon Business, AT&T, British Telecom, NTT and Deutsche Telekom.
Advisors' Opinion:- [By The GeoTeam]
This brings us to Global Telecom (GTT), a company that provides customers with innovative connectivity solutions by utilizing its own network assets.
Top 5 Tech Stocks To Own For 2014: Hewlett-Packard Company(HPQ)
Hewlett-Packard Company and its subsidiaries provide products, technologies, software, solutions, and services to individual consumers and small- and medium-sized businesses (SMBs), as well as to the government, health, and education sectors worldwide. Its Personal Systems Group segment offers commercial personal computers (PCs), consumer PCs, workstations, calculators and other related accessories, and software and services for the commercial and consumer markets. The company?s Services segment provides consulting, outsourcing, and technology services to infrastructure, applications, and business process domains. Its Imaging and Printing Group segment provides consumer and commercial printer hardware, supplies, media, and scanning devices, such as inkjet and Web solutions, laser jet and enterprise solutions, managed enterprise solutions, graphics solutions, and printer supplies. The company?s Enterprise Servers, Storage, and Networking segment offers industry standard s ervers, business critical systems, storage platforms, and networking products, including switches, routers, wireless LAN, and TippingPoint network security products. Its HP Software segment provides enterprise IT management software, information management solutions, and security intelligence/risk management solutions. The company?s HP Financial Services segment offers leasing, financing, utility programs, and asset recovery services; and financial asset management services for enterprise customers, as well as specialized financial services to SMBs, and educational and governmental entities. Hewlett-Packard Company also provides business intelligence solutions that enable businesses to standardize on consistent data management schemes, connect and share data across the enterprise, and apply analytics, as well as licenses its specific technology to third parties. The company was founded in 1939 and is headquartered in Palo Alto, California.
Advisors' Opinion:- [By Dan Caplinger]
The big but hopefully short-term problem
Of course, the worst payout ratio to have is a negative one, and that's the situation that Hewlett-Packard (NYSE: HPQ ) finds itself in. But those losses largely come from one-time impairments that slashed about $9 per share from earnings last year. Once the negative impact of those writedowns disappears from the income statement, payout ratios should revert to their more traditional levels, which have typically ranged from 10% to 15% since 2006.
No comments:
Post a Comment